High concentrations of subtype 2 somatostatin tumor receptors (sst2) are expressed in numerous tumors, enabling primary and metastatic masses to be localized by scintigraphy after injecting 111In-labeled somatostatin analogue octreotide. In addition to neuroendocrine tumors, somatostatin receptors have been identified on cancers of the central nervous system, breast, lung, and lymphatic tissue, and the use of radionuclide-labeled somatostatin analogues appeared promising for therapy as well as for diagnosis of such malignancies. The somatostatin analogue [DOTA-DPhe1-Tyr3] octreotide (DOTATOC) possesses favorable characteristics for its potential therapeutic use in that it shows high affinity for sst2, moderately high affinity for sst5, and intermediate affinity for sst3, high hydrophilicity, stable and facile labeling with 111In and 90Y. We began to investigate the potential therapeutic applications of 90Y DOTATOC in 1997 by performing a thorough dosimetric study in 18 patients who were administered 111In DOTATOC to estimate the absorbed doses during 90Y-DOTATOC therapy. Then, we moved on and treated an overall number of 256 patients, mostly recruited in 2 distinct protocols with and without the administration of kidney protecting agents, with 90Y DOTATOC. No major acute reactions were observed up to the activity of 5.55 GBq per cycle, The MTD per cycle was defined as 5.18 GBq. Objective therapeutic responses were documented in more than 20% of patients in terms of partial and complete responses. The present article reports in details our clinical experience (still ongoing) and outcomes with the use of 90Y DOTATOC.
|Number of pages||7|
|Journal||Seminars in Nuclear Medicine|
|Publication status||Published - 2002|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Radiological and Ultrasound Technology